SCHEMBL2402152

SCHEMBL2402152

CC(C)C(=O)OCC(COC(=O)C(C)C)OC(=O)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
PRKCA P17252 4/20 0.37
SERPINE1 P05121 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6141545 0.91 PRKCA (0.37) ALDH1A1LMNAPRKCA
SCHEMBL7478992 0.89 PRKCA (0.34) ALDH1A1LMNAPRKCA
SCHEMBL1838799 0.89 PRKCA (0.50) PRKCA
SCHEMBL23156004 0.87 PRKCA (0.33) ALDH1A1LMNAPRKCA
SCHEMBL26658338 0.86 PRKCA (0.53) ALDH1A1LMNAPRKCA
SCHEMBL12597761 0.84 ENPP2 (0.50)
SCHEMBL25276652 0.84 ALDH1A1 (0.52) ALDH1A1LMNAPRKCA
SCHEMBL17866531 0.82 ALDH1A1 (0.46) ALDH1A1LMNAPRKCA
SCHEMBL19034592 0.82 ADRB2 (0.37)
SCHEMBL19034633 0.82 ABCB1 (0.31) PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064295-A1 A WATERBORNE BINDER COMPOSITION AND USE THEREOF Perstorp Specialty Chemicals AB (SE) 2009-06-03 EP claimed
WO-2008054277-A1 A WATERBORNE BINDER COMPOSITION AND USE THEREOF PERSTORP SPECIALTY CHEMICALS AB (SE) 2008-05-08 WO claimed
EP-4619017-A1 ANTIBIOTIC-RESISTANT BACTERIA Imperial College Innovations Limited (GB) 2025-09-24 EP disclosed
US-20240366723-A1 COMBINATION THERAPY FOR THE TREATMENT OF ENTERIC NEUROPATHIES UNIVERSITÉ DU QUÉBEC À MONTRÉAL (CA) 2024-11-07 US disclosed
WO-2024105412-A1 ANTIBIOTIC-RESISTANT BACTERIA IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2024-05-23 WO disclosed
EP-4355354-A1 COMBINATION THERAPY FOR THE TREATMENT OF ENTERIC NEUROPATHIES Transfert Plus Limited Partnership (CA) 2024-04-24 EP disclosed
WO-2022261765-A1 COMBINATION THERAPY FOR THE TREATMENT OF ENTERIC NEUROPATHIES SORET RODOLPHE (CA) 2022-12-22 WO disclosed
EP-2740497-B1 Medical adhesive compound AESCULAP AG (DE) 2017-12-06 EP disclosed
EP-2366721-B1 Medical kit for use during negative pressure wound therapy AESCULAP AG (DE) 2016-08-10 EP disclosed
EP-2223706-B1 Medical adhesive compound AESCULAP AG (DE) 2014-09-03 EP disclosed
EP-2740497-A1 Medical adhesive compound Aesculap AG (DE) 2014-06-11 EP disclosed
EP-0584159-A1 NUTRIENT PREPARATION. FRESENIUS AG (DE) 1994-03-02 EP disclosed
US-5248531-A TRIGLYCERIDE TERUMO KABUSHIKI KAISHA (JP) 1993-09-28 US disclosed
EP-0340305-B1 HEMOLYSIS INHIBITOR AND PLASTICIZER Kao Corporation (JP) 1993-04-21 EP disclosed
WO-1992020241-A1 NUTRIENT PREPARATION FRESENIUS AG (DE) 1992-11-26 WO disclosed
US-5079002-A During blood preservation; ccontacting erythrocyte with a triglyceride compound TERUMO KABUSHIKI KAISHA (JP) 1992-01-07 US disclosed
US-4927754-A Method for selectively increasing the ratio of single major components of teicoplanin A2 complex GRUPPO LEPETIT S.P.A. (IT) 1990-05-22 US disclosed
EP-0204179-B1 METHOD FOR SELECTIVELY INCREASING THE RATIO OF SINGLE MAJOR COMPONENTS OF TEICOPLANIN A2 COMPLEX GRUPPO LEPETIT S.p.A. (IT) 1989-11-08 EP disclosed
EP-0340305-A1 HEMOLYSIS INHIBITOR AND PLASTICIZER Kao Corporation (JP) 1989-11-08 EP disclosed
EP-0204179-A1 Method for selectively increasing the ratio of single major components of teicoplanin A2 complex GRUPPO LEPETIT S.p.A. (IT) 1986-12-10 EP disclosed